E-selectin ligand 1 regulates bone remodeling by limiting bioactive TGF-β in the bone microenvironment

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 18, 2013, Pages 7336-7341

  Yang, Tao ^a,d   Grafe, Ingo ^a   Bae, Yangjin ^a   Chen, Shan ^a   Chen, Yuqing ^a,b   Terry K Bertin, ^a   Jiang, Ming Ming ^a,b   Ambrose, Catherine G ^c   Lee, Brendan ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

1D11 antibody; Osteoblast mineralization; Osteoporosis

Indexed keywords

COLLAGENASE 3; CONNECTIVE TISSUE GROWTH FACTOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PARATHYROID HORMONE RELATED PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MASS; BONE MINERALIZATION; BONE REMODELING; CELL CULTURE; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; DISEASE SEVERITY; HOMEOSTASIS; MALE; MICROENVIRONMENT; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPENIA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIBODIES; BONE DISEASES, METABOLIC; BONE REMODELING; BONE RESORPTION; CALCIFICATION, PHYSIOLOGIC; CELL DIFFERENTIATION; CELL LINEAGE; CELLS, CULTURED; FEMUR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HOMEOSTASIS; MICE; ORGAN SIZE; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; PHENOTYPE; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIALOGLYCOPROTEINS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

MUS;

EID: 84876932338     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1219748110     Document Type: Article

References (36)

1. Feng X, McDonald JM (2011) Disorders of bone remodeling. Annu Rev Pathol 6:121-145.
2. Janssens K, ten Dijke P, Janssens S, Van Hul W (2005) Transforming growth factor-beta1 to the bone. Endocr Rev 26(6):743-774.
3. Serra R, Chang C (2003) TGF-beta signaling in human skeletal and patterning disorders. Birth Defects Res C Embryo Today 69(4):333-351. (Pubitemid 38076457)
4. Edwards JR, et al. (2010) Inhibition of TGF-β signaling by 1D11 antibody treatment increases bone mass and quality in vivo. J Bone Miner Res 25(11):2419-2426.
5. Mohammad KS, et al. (2009) Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS One 4(4):e5275.
6. Dabovic B, et al. (2002) Bone abnormalities in latent TGF-[beta] binding protein (Ltbp)-3-null mice indicate a role for Ltbp-3 in modulating TGF-[beta] bioavailability. J Cell Biol 156(2):227-232. (Pubitemid 34839904)
7. Erlebacher A, Derynck R (1996) Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype. J Cell Biol 132(1-2):195-210.
8. Filvaroff E, et al. (1999) Inhibition of TGF-beta receptor signaling in osteoblasts leads to decreased bone remodeling and increased trabecular bone mass. Development 126(19):4267-4279. (Pubitemid 29509342)
9. Janssens K, et al. (2000) Mutations in the gene encoding the latency-associated peptide of TGF-beta 1 cause Camurati-Engelmann disease. Nat Genet 26(3):273-275.
10. Tang Y, et al. (2009) TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med 15(7):757-765.
11. Annes JP, Munger JS, Rifkin DB (2003) Making sense of latent TGFbeta activation. J Cell Sci 116(Pt 2):217-224. (Pubitemid 36163863)
12. Dubois CM, Laprise MH, Blanchette F, Gentry LE, Leduc R (1995) Processing of transforming growth factor beta 1 precursor by human furin convertase. J Biol Chem 270(18):10618-10624.
13. Miyazono K, Thyberg J, Heldin CH (1992) Retention of the transforming growth factor-beta 1 precursor in the Golgi complex in a latent endoglycosidase H-sensitive form. J Biol Chem 267(8):5668-5675.
14. Le Goff C, et al. (2008) ADAMTSL2 mutations in geleophysic dysplasia demonstrate a role for ADAMTS-like proteins in TGF-beta bioavailability regulation. Nat Genet 40(9):1119-1123.
15. Burrus LW, Zuber ME, Lueddecke BA, Olwin BB (1992) Identification of a cysteine-rich receptor for fibroblast growth factors. Mol Cell Biol 12(12):5600-5609.
16. Steegmaier M, et al. (1995) The E-selectin-ligand ESL-1 is a variant of a receptor for fibroblast growth factor. Nature 373(6515):615-620.
17. Olofsson A, et al. (1997) Latent transforming growth factor-beta complex in Chinese hamster ovary cells contains the multifunctional cysteine-rich fibroblast growth factor receptor, also termed E-selectin-ligand or MG-160. Biochem J 324(Pt 2):427-434. (Pubitemid 27267984)
18. Stieber A, Mourelatos Z, Chen YJ, Le Douarin N, Gonatas NK (1995) MG160, a membrane protein of the Golgi apparatus which is homologous to a fibroblast growth factor receptor and to a ligand for E-selectin, is found only in the Golgi apparatus and appears early in chicken embryo development. Exp Cell Res 219(2):562-570.
19. Yang T, et al. (2010) E-selectin ligand-1 regulates growth plate homeostasis in mice by inhibiting the intracellular processing and secretion of mature TGF-beta. J Clin Invest 120(7):2474- 2485.
20. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423(6937):337-342. (Pubitemid 40852708)
21. Bonewald LF, et al. (1991) Latent forms of transforming growth factor-beta (TGF beta) derived from bone cultures: Identification of a naturally occurring 100-kDa complex with similarity to recombinant latent TGF beta. Mol Endocrinol 5(6):741-751. (Pubitemid 21923727)
22. Dallas SL, et al. (1994) Characterization and autoregulation of latent transforming growth factor beta (TGF beta) complexes in osteoblast-like cell lines. Production of a latent complex lacking the latent TGF beta-binding protein. J Biol Chem 269(9):6815-6821.
23. Liu B, Goltzman D, Rabbani SA (1995) Processing of pro-PTHRP by the prohormone convertase, furin: Effect on biological activity. Am J Physiol 268(5 Pt 1):E832-E838.
24. Siegfried G, et al. (2003) The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis. J Clin Invest 111(11):1723-1732. (Pubitemid 38057753)
25. Balooch G, et al. (2005) TGF-beta regulates the mechanical properties and composition of bone matrix. Proc Natl Acad Sci USA 102(52):18813-18818. (Pubitemid 43049527)
26. Zacchigna L, et al. (2006) Emilin1 links TGF-beta maturation to blood pressure homeostasis. Cell 124(5):929-942. (Pubitemid 43344234)
27. Biswas S, et al. (2011) Anti-transforming growth factor β antibody treatment rescues bone loss and prevents breast cancer metastasis to bone. PLoS One 6(11):e27090.
28. Kang JS, Alliston T, Delston R, Derynck R (2005) Repression of Runx2 function by TGFbeta through recruitment of class II histone deacetylases by Smad3. EMBO J 24(14):2543-2555. (Pubitemid 41076311)
29. Smerdel-Ramoya A, Zanotti S, Stadmeyer L, Durant D, Canalis E (2008) Skeletal overexpression of connective tissue growth factor impairs bone formation and causes osteopenia. Endocrinology 149(9):4374-4381.
30. Stickens D, et al. (2004) Altered endochondral bone development in matrix metalloproteinase 13-deficient mice. Development 131(23):5883-5895. (Pubitemid 40123905)
31. Nistala H, Lee-Arteaga S, Smaldone S, Siciliano G, Ramirez F (2010) Extracellular microfibrils control osteoblast-supported osteoclastogenesis by restricting TGFbeta stimulation of RANKL production. J Biol Chem 285(44):34126-34133.
32. Miao D, et al. (2005) Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. J Clin Invest 115(9):2402-2411. (Pubitemid 41266202)
33. Horwitz MJ, et al. (2011) A 7-day continuous infusion of PTH or PTHrP suppresses bone formation and uncouples bone turnover. J Bone Miner Res 26(9):2287-2297.
34. Ikeda K, et al. (1988) Identification of transcripts encoding a parathyroid hormone-like peptide in messenger RNAs from a variety of human and animal tumors associated with humoral hypercalcemia of malignancy. J Clin Invest 81(6):2010-2014.
35. Grover M, et al. (2012) Assessment of bone mineral status in children with Marfan syndrome. Am J Med Genet A 158A(9):2221-2224.
36. Neptune ER, et al. (2003) Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 33(3):407-411. (Pubitemid 36278859)